Similarly, Vestad et al. (2022) investigated the alteration in gut microbiota composition as well as the levels of the gut barrier dysfunction marker lipopolysaccharide-binding protein (LBP) in patients with persistent pulmonary dysfunction at month 3 after COVID-19 compared with patients without persistent respiratory dysfunction [34]. The gene discussed is LBP; the disease is COVID-19.